PHATHOM PHARMACEUTICALS, INC. Net Income
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Net Income of -$17.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$17.58M.
- PHATHOM PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$30.37M.
- PHATHOM PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $199.88M, a 22.99% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$29.97M.
- PHATHOM PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2022 was -$197.72M.
- PHATHOM PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2021 was -$143.88M.
- PHATHOM PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2020 was -$129.07M.
- PHATHOM PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2019 was -$255.13M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$17.58M 10-Q · filed 2026-07-30 | -$47.95M 10-Q · filed 2026-07-30 | $151.93M derived: sum of 3 quarters · filed 2026-07-30 | $121.95M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | -$30.37M 10-Q · filed 2026-07-30 | $169.51M derived: sum of 2 quarters · filed 2026-07-30 | $139.54M derived: sum of 3 quarters · filed 2026-07-30 | $63.73M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | $199.88M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-07 | $169.90M derived: sum of 2 quarters · filed 2026-04-07 | $94.09M derived: sum of 3 quarters · filed 2026-07-30 | -$221.25K DEF 14A · filed 2026-04-07 | -$221.25M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$29.97M 10-Q · filed 2025-10-30 | -$105.78M derived: sum of 2 quarters · filed 2026-07-30 | -$200.10M 10-Q · filed 2025-10-30 | $59.44M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | -$75.81M 10-Q · filed 2026-07-30 | -$170.13M 10-Q · filed 2026-07-30 | $89.41M derived: sum of 3 quarters · filed 2026-07-30 | $3.84M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | -$94.32M 10-Q · filed 2026-07-30 | $165.22M derived: sum of 2 quarters · filed 2026-07-30 | $79.65M derived: sum of 3 quarters · filed 2026-07-30 | -$11.80M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2024-12-31 | $259.54M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-07 | $173.96M derived: sum of 2 quarters · filed 2026-04-07 | $82.52M derived: sum of 3 quarters · filed 2026-04-07 | -$334.33K DEF 14A · filed 2026-04-07 | -$334.33M 10-K · filed 2025-03-06 |
| 2024-09-30 | -$85.58M 10-Q · filed 2025-10-30 | -$177.02M derived: sum of 2 quarters · filed 2025-10-30 | -$259.88M 10-Q · filed 2025-10-30 | -$138.05M derived: sum of 4 quarters · filed 2026-04-07 | |
| 2024-06-30 | -$91.45M 10-Q · filed 2025-10-30 | -$174.30M 10-Q · filed 2025-08-07 | -$52.48M derived: sum of 3 quarters · filed 2026-04-07 | -$95.72M derived: sum of 4 quarters · filed 2026-04-07 | |
| 2024-03-31 | -$82.85M 10-Q · filed 2025-10-30 | $38.97M derived: sum of 2 quarters · filed 2026-04-07 | -$4.27M derived: sum of 3 quarters · filed 2026-04-07 | -$45.24M derived: sum of 4 quarters · filed 2026-04-07 | |
| 2023-12-31 | $121.82M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-07 | $78.58M derived: sum of 2 quarters · filed 2026-04-07 | $37.61M derived: sum of 3 quarters · filed 2026-04-07 | -$201.59K DEF 14A · filed 2026-04-07 | -$201.59M 10-K · filed 2024-03-07 |
| 2023-09-30 | -$43.24M 10-Q · filed 2024-11-07 | -$84.21M derived: sum of 2 quarters · filed 2024-11-07 | -$122.02M 10-Q · filed 2024-11-07 | -$177.07M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$40.97M 10-Q · filed 2024-11-07 | -$78.78M 10-Q · filed 2024-08-08 | -$133.83M derived: sum of 3 quarters · filed 2024-11-07 | -$184.92M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-03-31 | -$37.81M 10-Q · filed 2024-11-07 | -$92.86M derived: sum of 2 quarters · filed 2024-11-07 | -$143.95M derived: sum of 3 quarters · filed 2024-11-07 | -$194.87M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2022-12-31 | -$55.05M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | -$106.14M derived: sum of 2 quarters · filed 2024-06-14 | -$157.06M derived: sum of 3 quarters · filed 2024-06-14 | -$197.72M 10-K/A · filed 2024-06-14 | |
| 2022-09-30 | -$51.09M 10-Q · filed 2023-11-09 | -$102.01M derived: sum of 2 quarters · filed 2023-11-09 | -$142.68M 10-Q · filed 2023-11-09 | -$178.50M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$50.92M 10-Q · filed 2023-11-09 | -$91.58M 10-Q · filed 2023-08-10 | -$127.41M derived: sum of 3 quarters · filed 2023-11-09 | -$164.07M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-03-31 | -$40.66M 10-Q · filed 2023-11-09 | -$76.49M derived: sum of 2 quarters · filed 2023-11-09 | -$113.15M derived: sum of 3 quarters · filed 2023-11-09 | -$149.71M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2021-12-31 | -$35.83M derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | -$72.49M derived: sum of 2 quarters · filed 2023-02-28 | -$109.04M derived: sum of 3 quarters · filed 2023-02-28 | -$143.88M 10-K · filed 2023-02-28 | |
| 2021-09-30 | -$36.66M 10-Q/A · filed 2022-11-09 | -$73.21M derived: sum of 2 quarters · filed 2022-11-09 | -$108.06M 10-Q/A · filed 2022-11-09 | -$161.78M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | -$36.55M 10-Q/A · filed 2022-11-09 | -$71.39M 10-Q · filed 2022-08-02 | -$125.12M derived: sum of 3 quarters · filed 2022-11-09 | -$159.22M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-03-31 | -$34.84M 10-Q/A · filed 2022-11-09 | -$88.56M derived: sum of 2 quarters · filed 2022-11-09 | -$122.67M derived: sum of 3 quarters · filed 2022-11-09 | -$143.77M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2020-12-31 | -$53.72M 10-K · filed 2021-03-30 | -$87.83M derived: sum of 2 quarters · filed 2021-11-08 | -$108.93M derived: sum of 3 quarters · filed 2021-11-08 | -$129.07M 10-K · filed 2022-03-01 | |
| 2020-09-30 | -$34.10M 10-Q · filed 2021-11-08 | -$55.21M derived: sum of 2 quarters · filed 2021-11-08 | -$75.35M 10-Q · filed 2021-11-08 | -$173.35M derived: sum of 4 quarters · filed 2021-11-08 | |
| 2020-06-30 | -$21.10M 10-Q · filed 2021-11-08 | -$41.24M 10-Q · filed 2021-08-10 | -$139.25M derived: sum of 3 quarters · filed 2021-11-08 | -$207.36M derived: sum of 4 quarters · filed 2021-11-08 | |
| 2020-03-31 | -$20.14M 10-Q · filed 2021-11-08 | -$118.15M derived: sum of 2 quarters · filed 2021-11-08 | -$186.26M derived: sum of 3 quarters · filed 2021-11-08 | -$274.02M derived: sum of 4 quarters · filed 2021-11-08 | |
| 2019-12-31 | -$98.01M 10-K · filed 2021-03-30 | -$166.12M derived: sum of 2 quarters · filed 2021-03-30 | -$253.88M derived: sum of 3 quarters · filed 2021-03-30 | -$255.13M 10-K · filed 2021-03-30 | |
| 2019-09-30 | -$68.11M 10-K · filed 2021-03-30 | -$155.87M derived: sum of 2 quarters · filed 2021-03-30 | -$157.13M 10-Q · filed 2020-11-10 | -$157.61M derived: sum of 4 quarters · filed 2021-03-30 | |
| 2019-06-30 | -$87.76M 10-K · filed 2021-03-30 | -$89.01M 10-Q · filed 2020-08-06 | -$89.50M derived: sum of 3 quarters · filed 2021-03-30 | -$89.79M derived: sum of 4 quarters · filed 2021-03-30 | |
| 2019-03-31 | -$1.25M 10-K · filed 2021-03-30 | -$1.74M derived: sum of 2 quarters · filed 2021-03-30 | -$2.02M derived: sum of 3 quarters · filed 2021-03-30 | -$2.29M derived: sum of 4 quarters · filed 2021-03-30 | |
| 2018-12-31 | -$484.00K 10-K · filed 2020-03-19 | -$774.00K derived: sum of 2 quarters · filed 2020-03-19 | -$1.03M derived: sum of 3 quarters · filed 2020-03-19 | -$1.29M 10-K · filed 2020-03-19 | |
| 2018-09-30 | -$290.00K 10-K · filed 2020-03-19 | -$550.00K derived: sum of 2 quarters · filed 2020-03-19 | -$804.00K 10-Q · filed 2019-11-25 | ||
| 2018-06-30 | -$260.00K 10-K · filed 2020-03-19 | -$514.00K derived: sum of 2 quarters · filed 2020-03-19 | |||
| 2018-03-31 | -$254.00K 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |